vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and PROGRESS SOFTWARE CORP (PRGS). Click either name above to swap in a different company.

PROGRESS SOFTWARE CORP is the larger business by last-quarter revenue ($252.7M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 17.5%). Over the past eight quarters, PROGRESS SOFTWARE CORP's revenue compounded faster (17.0% CAGR vs 10.6%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Progress Software Corporation develops and sells enterprise software products including application development platforms, data connectivity tools, and digital experience solutions. It serves global enterprise clients across finance, healthcare, manufacturing, retail and other sectors, helping organizations build scalable, high-performance business applications and streamline operational workflows.

ESPR vs PRGS — Head-to-Head

Bigger by revenue
PRGS
PRGS
1.5× larger
PRGS
$252.7M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+126.2% gap
ESPR
143.7%
17.5%
PRGS
Faster 2-yr revenue CAGR
PRGS
PRGS
Annualised
PRGS
17.0%
10.6%
ESPR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
PRGS
PRGS
Revenue
$168.4M
$252.7M
Net Profit
$25.7M
Gross Margin
81.6%
Operating Margin
50.6%
15.2%
Net Margin
10.2%
Revenue YoY
143.7%
17.5%
Net Profit YoY
2144.6%
EPS (diluted)
$0.32
$0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
PRGS
PRGS
Q4 25
$168.4M
$252.7M
Q3 25
$87.3M
$249.8M
Q2 25
$82.4M
$237.4M
Q1 25
$65.0M
$238.0M
Q4 24
$69.1M
$215.0M
Q3 24
$51.6M
$178.7M
Q2 24
$73.8M
$175.1M
Q1 24
$137.7M
$184.7M
Net Profit
ESPR
ESPR
PRGS
PRGS
Q4 25
$25.7M
Q3 25
$-31.3M
$19.4M
Q2 25
$-12.7M
$17.0M
Q1 25
$-40.5M
$10.9M
Q4 24
$1.1M
Q3 24
$-29.5M
$28.5M
Q2 24
$-61.9M
$16.2M
Q1 24
$61.0M
$22.6M
Gross Margin
ESPR
ESPR
PRGS
PRGS
Q4 25
81.6%
Q3 25
81.0%
Q2 25
80.1%
Q1 25
80.6%
Q4 24
83.0%
Q3 24
83.7%
Q2 24
81.7%
Q1 24
82.2%
Operating Margin
ESPR
ESPR
PRGS
PRGS
Q4 25
50.6%
15.2%
Q3 25
-11.4%
17.6%
Q2 25
8.6%
16.3%
Q1 25
-34.0%
13.6%
Q4 24
-6.4%
10.0%
Q3 24
-31.0%
22.6%
Q2 24
3.5%
15.5%
Q1 24
52.5%
19.0%
Net Margin
ESPR
ESPR
PRGS
PRGS
Q4 25
10.2%
Q3 25
-35.9%
7.8%
Q2 25
-15.4%
7.2%
Q1 25
-62.2%
4.6%
Q4 24
0.5%
Q3 24
-57.2%
15.9%
Q2 24
-83.9%
9.2%
Q1 24
44.3%
12.3%
EPS (diluted)
ESPR
ESPR
PRGS
PRGS
Q4 25
$0.32
$0.59
Q3 25
$-0.16
$0.44
Q2 25
$-0.06
$0.39
Q1 25
$-0.21
$0.24
Q4 24
$-0.14
$0.01
Q3 24
$-0.15
$0.65
Q2 24
$-0.33
$0.37
Q1 24
$0.34
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
PRGS
PRGS
Cash + ST InvestmentsLiquidity on hand
$167.9M
$94.8M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$-302.0M
$478.3M
Total Assets
$465.9M
$2.5B
Debt / EquityLower = less leverage
2.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
PRGS
PRGS
Q4 25
$167.9M
$94.8M
Q3 25
$92.4M
$99.0M
Q2 25
$86.1M
$102.0M
Q1 25
$114.6M
$124.2M
Q4 24
$144.8M
$118.1M
Q3 24
$144.7M
$232.7M
Q2 24
$189.3M
$190.4M
Q1 24
$226.6M
$133.2M
Total Debt
ESPR
ESPR
PRGS
PRGS
Q4 25
$1.4B
Q3 25
$1.4B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.5B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ESPR
ESPR
PRGS
PRGS
Q4 25
$-302.0M
$478.3M
Q3 25
$-451.4M
$477.7M
Q2 25
$-433.5M
$452.7M
Q1 25
$-426.2M
$431.8M
Q4 24
$-388.7M
$438.8M
Q3 24
$-370.2M
$425.6M
Q2 24
$-344.2M
$401.7M
Q1 24
$-294.3M
$461.7M
Total Assets
ESPR
ESPR
PRGS
PRGS
Q4 25
$465.9M
$2.5B
Q3 25
$364.0M
$2.4B
Q2 25
$347.1M
$2.4B
Q1 25
$324.0M
$2.5B
Q4 24
$343.8M
$2.5B
Q3 24
$314.1M
$1.6B
Q2 24
$352.3M
$1.6B
Q1 24
$373.1M
$1.5B
Debt / Equity
ESPR
ESPR
PRGS
PRGS
Q4 25
2.93×
Q3 25
2.97×
Q2 25
3.22×
Q1 25
3.50×
Q4 24
3.48×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
PRGS
PRGS
Operating Cash FlowLast quarter
$45.2M
$62.8M
Free Cash FlowOCF − Capex
$59.9M
FCF MarginFCF / Revenue
23.7%
Capex IntensityCapex / Revenue
0.0%
1.1%
Cash ConversionOCF / Net Profit
2.44×
TTM Free Cash FlowTrailing 4 quarters
$229.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
PRGS
PRGS
Q4 25
$45.2M
$62.8M
Q3 25
$-4.3M
$73.4M
Q2 25
$-31.4M
$30.0M
Q1 25
$-22.6M
$68.9M
Q4 24
$-35.0M
$19.7M
Q3 24
$-35.3M
$57.7M
Q2 24
$-7.2M
$63.7M
Q1 24
$53.8M
$70.5M
Free Cash Flow
ESPR
ESPR
PRGS
PRGS
Q4 25
$59.9M
Q3 25
$72.4M
Q2 25
$29.5M
Q1 25
$67.7M
Q4 24
$16.8M
Q3 24
$-35.5M
$56.6M
Q2 24
$-7.3M
$62.7M
Q1 24
$53.8M
$70.2M
FCF Margin
ESPR
ESPR
PRGS
PRGS
Q4 25
23.7%
Q3 25
29.0%
Q2 25
12.4%
Q1 25
28.4%
Q4 24
7.8%
Q3 24
-68.7%
31.7%
Q2 24
-9.9%
35.8%
Q1 24
39.0%
38.0%
Capex Intensity
ESPR
ESPR
PRGS
PRGS
Q4 25
0.0%
1.1%
Q3 25
0.0%
0.4%
Q2 25
0.0%
0.2%
Q1 25
0.0%
0.5%
Q4 24
0.0%
1.3%
Q3 24
0.3%
0.6%
Q2 24
0.1%
0.5%
Q1 24
0.1%
0.2%
Cash Conversion
ESPR
ESPR
PRGS
PRGS
Q4 25
2.44×
Q3 25
3.78×
Q2 25
1.76×
Q1 25
6.30×
Q4 24
17.13×
Q3 24
2.03×
Q2 24
3.93×
Q1 24
0.88×
3.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

PRGS
PRGS

Maintenanceand Services$187.5M74%
Share File Acquisition$67.5M27%

Related Comparisons